NLRP3 Inflammasome activation model
Target neuroinflammation in Parkinson’s disease by studying the therapeutic effects on the NLRP3 pathway activation using the NLRP3 inflammasome activation model
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD.
Neuroinflammation plays a key role in the pathophysiology of PD, whereby NLRP3 inflammasome activation represents the key component of neuroinflammation.
Studying NLPR3 activation in vivo:
- MPTP administration leads to robust inflammation in the substantia nigra (SN).
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs

Key readouts
Test the efficacy of your treatments in the following battery of behavioural tests:
- (Digital) histopathology
- Immunohistochemistry (dopamine neurons, neuroinflammation)
- Immunofluorescence and FISH

Mice injected with MPTP have robust inflammasome activation in the substantia nigra (SN), as detected by fluorescence immunohistochemistry (IHC)
Iba1 signal (red) shows microgliosis. Asc signal (green) staining shows NLRP3 inflammasome activation. Asc signal co-localizes with Iba1-positive microglia (overlay). Nuclei (blue) were detected by DAPI.
Related Parkinson’s Disease model options
MPTP Induced PD Models
Transgenic Alpha-Synuclein Models
Seeding Alpha-Synuclein Models
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know